{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:05Z","timestamp":1792607945479,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020510","name":"Johnson and Johnson KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.medj.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:58:39Z","timestamp":1666004319000},"page":"860-882.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis"],"prefix":"10.1016","volume":"3","author":[{"given":"Suzanne","family":"Edavettal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Cejudo-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidisha","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Buschman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Van Kolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pharavee","family":"Jaiprasat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Schutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille Helene","family":"Soubrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Van Der Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"LaCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zemeda","family":"Ainekulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilyn","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aligo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Lebowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Scheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9119-7966","authenticated-orcid":false,"given":"Sanjaya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2022.09.007_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.medj.2022.09.007_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2022.09.007_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2022.09.007_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.medj.2022.09.007_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.neurobiolaging.2006.05.016","article-title":"Microvascular injury and blood-brain barrier leakage in Alzheimer\u2019s disease","volume":"28","author":"Zipser","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.medj.2022.09.007_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib7","doi-asserted-by":"crossref","first-page":"e20190062","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/pharmaceutics12010062","article-title":"Antibodies for the treatment of brain metastases, a dream or a reality?","volume":"12","author":"Cavaco","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.medj.2022.09.007_bib9","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.3390\/ijms22126442","article-title":"Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2022.09.007_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of\u00a0therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2022.09.007_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40266-016-0406-x","article-title":"Antibody-based drugs and approaches against amyloid-\u03b2 species for Alzheimer\u2019s disease immunotherapy","volume":"33","author":"Liu","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.medj.2022.09.007_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease: a systematic review and network meta-analysis","volume":"4","author":"Mo","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.medj.2022.09.007_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer\u2019s Disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.medj.2022.09.007_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3389\/fimmu.2019.01139","article-title":"The role of antibodies and their receptors in protection against ordered protein assembly in neurodegeneration","volume":"10","author":"Katsinelos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.medj.2022.09.007_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-015-1484-2","article-title":"Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies","volume":"130","author":"Fuller","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.medj.2022.09.007_bib17","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique a\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.medj.2022.09.007_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11357-020-00161-9","article-title":"Microglial autophagy is impaired by prolonged exposure to \u03b2-amyloid peptides: evidence from experimental models and Alzheimer\u2019s disease patients","volume":"42","author":"Pomilio","year":"2020","journal-title":"Geroscience"},{"key":"10.1016\/j.medj.2022.09.007_bib19","doi-asserted-by":"crossref","first-page":"183ra57","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib21","doi-asserted-by":"crossref","first-page":"eaay1359","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","article-title":"Brain shuttle antibody for Alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode","volume":"22","author":"Weber","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-019-0579-8","article-title":"Effector function of anti-pyroglutamate-3 A\u03b2 antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer\u2019s-like mice","volume":"12","author":"Crehan","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib24","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib25","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1038\/s41598-017-11220-1","article-title":"Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma","volume":"7","author":"Johnsen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpb.2016.01.009","article-title":"Mathematical PKPD and safety model of bispecific TfR\/BACE1 antibodies for the optimization of antibody uptake in brain","volume":"101","author":"Gadkar","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.medj.2022.09.007_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/psp4.12081","article-title":"Prospective design of anti-transferrin receptor bispecific antibodies for optimal delivery into the human brain","volume":"5","author":"Kanodia","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.medj.2022.09.007_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/19420862.2017.1359455","article-title":"Maximizing in\u00a0vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn","volume":"9","author":"Yang","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.medj.2022.09.007_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.sbi.2016.12.005","article-title":"Protein engineering approaches for regulating blood-brain barrier transcytosis","volume":"45","author":"Goulatis","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.medj.2022.09.007_bib30","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of immune complex size and glycosylation on IgG binding to human Fc rs","volume":"190","author":"Lux","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib31","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2022.09.007_bib32","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medj.2022.09.007_bib33","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/nm.4189","article-title":"Efficient derivation of microglia-like cells from human pluripotent stem cells","volume":"22","author":"Muffat","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neuron.2017.03.042","article-title":"iPSC-derived human microglia-like cells to study neurological diseases","volume":"94","author":"Abud","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2022.09.007_bib35","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.stemcr.2017.05.017","article-title":"A highly efficient human pluripotent stem cell microglia model displays a neuronal-Co-culture-Specific expression profile and inflammatory response","volume":"8","author":"Haenseler","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib36","first-page":"998","article-title":"Microglia immunophenotyping in gliomas","volume":"15","author":"Annovazzi","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.medj.2022.09.007_bib37","doi-asserted-by":"crossref","first-page":"12860","DOI":"10.1038\/s41598-019-49009-z","article-title":"L-type Amino acid transporter 1 (LAT1\/Lat1)-Utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia","volume":"9","author":"Huttunen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s42003-020-0842-3","article-title":"Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice","volume":"3","author":"Wuggenig","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.medj.2022.09.007_bib39","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.3390\/brainsci9050111","article-title":"Pro-inflammatory activation of A new immortalized human microglia cell line","volume":"9","author":"Chiavari","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.medj.2022.09.007_bib40","doi-asserted-by":"crossref","first-page":"e3001480","DOI":"10.1371\/journal.pbio.3001480","article-title":"Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia","volume":"19","author":"Mamais","year":"2021","journal-title":"PLoS Biol."},{"key":"10.1016\/j.medj.2022.09.007_bib41","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1172\/JCI126809","article-title":"Potential role of iron in repair of inflammatory demyelinating lesions","volume":"129","author":"Lee","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2022.09.007_bib42","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1007\/s12035-019-1519-0","article-title":"Transferrin enhances microglial phagocytic capacity","volume":"56","author":"Carden","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.medj.2022.09.007_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2013.10.013","article-title":"Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells","volume":"250","author":"Garrido-Gil","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.medj.2022.09.007_bib44","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.1074\/jbc.RA118.001949","article-title":"Inflammation-induced iron transport and metabolism by brain microglia","volume":"293","author":"McCarthy","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2022.09.007_bib45","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1074\/jbc.M409876200","article-title":"Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R\/2N transgenic mice","volume":"280","author":"Terwel","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2022.09.007_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-180404","article-title":"Anti-tau monoclonal antibodies derived from soluble and filamentous tau show diverse functional properties in\u00a0vitro and in\u00a0vivo","volume":"65","author":"Vandermeeren","year":"2018","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.medj.2022.09.007_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.medj.2022.09.007_bib48","doi-asserted-by":"crossref","first-page":"110776","DOI":"10.1016\/j.celrep.2022.110776","article-title":"Cholesterol determines the cytosolic entry and seeded aggregation of tau","volume":"39","author":"Tuck","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib49","doi-asserted-by":"crossref","first-page":"jcs213314","DOI":"10.1242\/jcs.213314","article-title":"Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6","volume":"131","author":"Finicle","year":"2018","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.medj.2022.09.007_bib50","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1600-0854.2009.00894.x","article-title":"Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis","volume":"10","author":"Eyster","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.medj.2022.09.007_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fnagi.2019.00308","article-title":"Tau phosphorylation in a mouse model of temporal lobe epilepsy","volume":"11","author":"Alves","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.medj.2022.09.007_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2018.04.051","article-title":"Phosphorylated nucleolar Tau protein is related to the neuronal in\u00a0vitro differentiation","volume":"664","author":"Federico","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.medj.2022.09.007_bib53","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1038\/s41598-019-48131-2","article-title":"Identification of a factor controlling lysosomal homeostasis using a novel lysosomal trafficking probe","volume":"9","author":"Ishii","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib54","doi-asserted-by":"crossref","first-page":"603640","DOI":"10.3389\/fimmu.2020.603640","article-title":"3D tumor models and their use for the testing of immunotherapies","volume":"11","author":"Boucherit","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib55","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3389\/fimmu.2019.00792","article-title":"Macrophage polarization in physiological and pathological pregnancy","volume":"10","author":"Yao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tips.2020.08.003","article-title":"Tackling TAMs for cancer immunotherapy: it\u2019s nano time","volume":"41","author":"Yang","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.medj.2022.09.007_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.medj.2022.09.007_bib58","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits amyloid-\u03b2 production in\u00a0vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib59","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.medj.2022.09.007_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2022.09.007_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2022.09.007_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.medj.2022.09.007_bib63","doi-asserted-by":"crossref","first-page":"101665","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.medj.2022.09.007_bib64","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib65","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1083\/jcb.129.6.1509","article-title":"Oligomerized transferrin receptors are selectively retained by a lumenal sorting signal in a long-lived endocytic recycling compartment","volume":"129","author":"Marsh","year":"1995","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.medj.2022.09.007_bib66","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","article-title":"Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules","volume":"24","author":"Weflen","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.medj.2022.09.007_bib67","doi-asserted-by":"crossref","first-page":"e20211057","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib68","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2011.196","article-title":"Transferrin antibodies into the brain","volume":"37","author":"Dennis","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.medj.2022.09.007_bib69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1471-4159.2001.00541.x","article-title":"Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat","volume":"79","author":"Moos","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.medj.2022.09.007_bib70","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00018-018-2982-x","article-title":"Intracellular transport and regulation of transcytosis across the blood-brain barrier","volume":"76","author":"Villase\u00f1or","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.medj.2022.09.007_bib71","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.celrep.2017.11.055","article-title":"Sorting tubules regulate blood-brain barrier transcytosis","volume":"21","author":"Villase\u00f1or","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","article-title":"Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier","volume":"81","author":"Schlachetzki","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.medj.2022.09.007_bib73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1208\/s12248-009-9129-9","article-title":"Investigation of the influence of FcRn on the distribution of IgG to the brain","volume":"11","author":"Garg","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.medj.2022.09.007_bib75","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/mp300214k","article-title":"Investigation of the role of Fc\u03b3R and FcRn in mAb distribution to the brain","volume":"10","author":"Abuqayyas","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.medj.2022.09.007_bib76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib77","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","article-title":"Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fc\u03b3-receptor binding and functional lysosomes","volume":"9","author":"Andersson","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib78","doi-asserted-by":"crossref","first-page":"862369","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.medj.2022.09.007_bib79","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2022.09.007_bib80","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/s41467-021-27737-z","article-title":"Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity","volume":"12","author":"Bido","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2022.09.007_bib81","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in\u00a0vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2022.09.007_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2022.09.007_bib83","doi-asserted-by":"crossref","first-page":"e96340","DOI":"10.1371\/journal.pone.0096340","article-title":"A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding","volume":"9","author":"Sade","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2022.09.007_bib84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/febs.13961","article-title":"Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity","volume":"284","author":"Zent","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.medj.2022.09.007_bib85","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nm.2048","article-title":"PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance","volume":"15","author":"Mukundan","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cei.12697","article-title":"Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages","volume":"183","author":"Church","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.medj.2022.09.007_bib87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2022.09.007_bib88","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1007\/s11095-016-2015-0","article-title":"Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in-vivo study","volume":"33","author":"Nounou","year":"2016","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.medj.2022.09.007_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/1535-7163.MCT-14-0399","article-title":"ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice","volume":"14","author":"Regina","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib90","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/jm9016637","article-title":"New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration","volume":"53","author":"Ch\u00e9","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.medj.2022.09.007_bib91","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2011.08.041","article-title":"Treatment of brain metastases: review of phase III randomized controlled trials","volume":"102","author":"Scoccianti","year":"2012","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib92","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/OTT.S293685","article-title":"Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets","volume":"14","author":"Lv","year":"2021","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","article-title":"EGFR mutation status on brain metastases from non-small cell lung cancer","volume":"96","author":"Hsu","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2022.09.007_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953729","article-title":"Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review","volume":"12","author":"Chan","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib95","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.medj.2022.09.007_bib97","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/annonc\/mdn036","article-title":"Defining prognosis for women with breast cancer and CNS metastases by HER2 status","volume":"19","author":"Dawood","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib98","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","article-title":"Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA","volume":"25","author":"Swain","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib99","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2022.09.007_bib100","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S1470-2045(22)00001-8","article-title":"Nivolumab plus ipilimumab in melanoma brain metastases","volume":"23","author":"Di Giacomo","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2020.11.009","article-title":"Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression","volume":"151","author":"Wakuda","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2022.09.007_bib102","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.medj.2022.09.007_bib103","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/17425247.2013.808184","article-title":"Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain-barrier divide","volume":"10","author":"Chacko","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.medj.2022.09.007_bib104","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-20-1097","article-title":"Valency of HER2 targeting antibodies influences tumor cell internalization and penetration","volume":"20","author":"Ramos","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.medj.2022.09.007_bib105","doi-asserted-by":"crossref","first-page":"e0157788","DOI":"10.1371\/journal.pone.0157788","article-title":"Enhancement of immune effector functions by modulating IgG\u2019s intrinsic affinity for target antigen","volume":"11","author":"Mazor","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2022.09.007_bib106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2014.08.032","article-title":"Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice","volume":"73","author":"Peeraer","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.medj.2022.09.007_bib107","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.medj.2022.09.007_bib108","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1073\/pnas.87.15.5827","article-title":"A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis","volume":"87","author":"Greenberg","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2022.09.007_bib109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00227819","article-title":"Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes","volume":"84","author":"Mercken","year":"1992","journal-title":"Acta Neuropathol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022004081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022004081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:56:37Z","timestamp":1763002597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634022004081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":109,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666634022004081"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2022.09.007","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}